Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

FDA Approval of Tisagenlecleucel

FDA Approval of Tisagenlecleucel This Viewpoint uses FDA approval of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) agent approved for human use, to discuss escalating drug prices for oncology therapies and the complex considerations of outcomes and value that should justify the pricing. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

FDA Approval of Tisagenlecleucel

JAMA , Volume 318 (19) – Nov 21, 2017

Loading next page...
 
/lp/american-medical-association/fda-approval-of-tisagenlecleucel-lDXkLZTLDi

References (8)

Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2017.15218
pmid
28975266
Publisher site
See Article on Publisher Site

Abstract

This Viewpoint uses FDA approval of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) agent approved for human use, to discuss escalating drug prices for oncology therapies and the complex considerations of outcomes and value that should justify the pricing.

Journal

JAMAAmerican Medical Association

Published: Nov 21, 2017

There are no references for this article.